Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ICAD 
icad inc (ICAD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: ICAD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
4 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $3.75
1 Year Target Price $3.75
| 0 | Strong Buy |
| 0 | Buy |
| 4 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -60.4% | Avg. Invested days 31 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 104.41M USD | Price to earnings Ratio - | 1Y Target Price 3.75 |
Price to earnings Ratio - | 1Y Target Price 3.75 | ||
Volume (30-day avg) 4 | Beta 1.4 | 52 Weeks Range 1.18 - 4.01 | Updated Date 06/30/2025 |
52 Weeks Range 1.18 - 4.01 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.19 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.77% | Operating Margin (TTM) -23.16% |
Management Effectiveness
Return on Assets (TTM) -9.03% | Return on Equity (TTM) -16.53% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 84680945 | Price to Sales(TTM) 5.35 |
Enterprise Value 84680945 | Price to Sales(TTM) 5.35 | ||
Enterprise Value to Revenue 4.34 | Enterprise Value to EBITDA -3.36 | Shares Outstanding 27260000 | Shares Floating 25747924 |
Shares Outstanding 27260000 | Shares Floating 25747924 | ||
Percent Insiders 5.51 | Percent Institutions 31.57 |
Analyst Ratings
Rating 2 | Target Price 3.75 | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold 4 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
icad inc
Company Overview
History and Background
iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire. It focuses on developing advanced image analysis and workflow solutions to improve cancer detection and treatment.
Core Business Areas
- Cancer Detection: Provides image analysis solutions, primarily for breast cancer detection using AI-powered software. Includes products for mammography and digital breast tomosynthesis (DBT).
- Radiation Therapy: Offers radiation therapy solutions, including advanced hardware and software for accurate and efficient radiation delivery.
Leadership and Structure
iCAD is led by CEO Dana Brown. The organizational structure includes departments for research and development, sales and marketing, operations, and finance. The Board of Directors oversees the company's strategic direction.
Top Products and Market Share
Key Offerings
- ProFound AI Risk: An AI-powered risk assessment tool used in conjunction with mammography to identify women at high risk for breast cancer. While specific market share data is unavailable, its competitors include Volpara Health (VHT.AX) and other AI-based detection systems. Revenue is not disclossed separately. Competitors also include Hologic (HOLX) and GE Healthcare (GE).
- Xoft Axxent eBx System: A miniature x-ray source used for intraoperative radiation therapy (IORT) and electronic brachytherapy (eBx) for early-stage breast cancer. Market share data is unavailable, but competitors include Elekta (EKTA-B.ST) and Varian Medical Systems (VAR).
Market Dynamics
Industry Overview
The cancer detection and treatment industry is experiencing growth, driven by technological advancements in AI, imaging, and radiation therapy. Increasing cancer incidence and awareness further fuel demand.
Positioning
iCAD is positioned as a technology innovator in AI-powered cancer detection and precision radiation therapy. Its competitive advantages include its proprietary AI algorithms and its Xoft eBx system for targeted radiation.
Total Addressable Market (TAM)
The global cancer diagnostics market is estimated to reach approximately $25 billion. The advanced radiation therapy market is estimated at $7 billion. iCAD is positioned to address significant portions of these markets through its innovative solutions.
Upturn SWOT Analysis
Strengths
- Innovative AI technology
- Proprietary Xoft eBx system
- Established relationships with healthcare providers
- Focus on cancer detection and treatment
Weaknesses
- Limited market share compared to larger competitors
- Dependence on regulatory approvals
- Financial performance variability
- Limited capital and salesforce
Opportunities
- Expanding applications of AI in cancer detection
- Increasing adoption of personalized medicine
- Growing demand for less invasive cancer treatments
- Strategic partnerships and acquisitions
Threats
- Competition from larger medical device companies
- Changes in reimbursement policies
- Technological obsolescence
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- HOLX
- VHT.AX
- EKTA-B.ST
Competitive Landscape
iCAD faces intense competition from larger, well-established medical device companies. Its strengths lie in its innovative AI technology and specialized radiation therapy solutions. However, it needs to overcome its limited market share and resources.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data not available.
Future Projections: Future projections based on analyst estimates are not readily available in the provided context.
Recent Initiatives: Recent initiatives include expanding the ProFound AI platform to new markets and clinical applications.
Summary
iCAD is a smaller player in the cancer detection and treatment market, primarily known for its AI-powered imaging solutions and innovative radiation therapy technologies. It has strong technologies, particularly in AI, but it faces stiff competition from larger, better-funded companies. A key challenge for iCAD is scaling its operations and sales efforts to compete effectively and to gain market share. Regulatory hurdles and dependence on technological innovation pose additional risks.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Press releases
Disclaimers:
The data provided is for informational purposes only and does not constitute financial advice. Market share data is based on estimations and may not be precise. Investment decisions should be based on thorough research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About icad inc
Exchange NASDAQ | Headquaters Nashua, NH, United States | ||
IPO Launch date 1986-12-03 | President, CEO & Executive Chair Ms. Dana R. Brown | ||
Sector Healthcare | Industry Medical Devices | Full time employees 66 | Website https://www.icadmed.com |
Full time employees 66 | Website https://www.icadmed.com | ||
iCAD, Inc. provides AI-powered cancer detection solutions in the United States. The company's ProFound Breast Health Suite offers solutions for"breast"cancer detection, breast density assessment, one- or two-year breast cancer risk evaluation, and cardiovascular risk assessment related to elevated levels of breast arterial calcifications; and enables medical providers and professionals to accurately and reliably identify where cancer may be hiding. Its Detection solutions include advanced artificial intelligence and image analysis workflow solutions to identifying pathologies and pinpointing prevalent cancers earlier; and a range of upgradeable computer-aided detection systems and workflow solutions for digital breast tomosynthesis, full-field digital mammography, magnetic resonance imaging, and computed tomography. In addition, the company suite offers solutions for cancer detection, density assessment, and personalized risk evaluation based on a 2D or 3D mammogram's collection of images. Additionally, its density assessment standardizes and simplifies breast density reporting by algorithmically examining a woman's breast anatomy from the mammogram image. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was incorporated in 1984 and is headquartered in Nashua, New Hampshire.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.